Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 5: Open-label safety study in adults and adolescents with haemophilia A switching from emicizumab to Mim8 (denecimig) prophylaxis
2022-502450-13-00Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Number of treatment-emergent adverse events (TEAEs). Started Jun 2023; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2022-502450-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502450-13-00.